Todas as matérias desta seção, das mais recentes às mais antigas — página 262 de 371.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo moved a step closer to a major label expansion for their blockbuster cancer therapy, Enhertu, after the U.S. FDA fast-tracked an application to treat patients with early-stage breast cancer at high risk of recurrence.
STMicroelectronics (NYSE:STM) has launched high-volume production of its PIC100 silicon photonics platform, positioning itself as a primary supplier for the 800G and 1.6T transceivers required to power the global AI infrastructure "super-cycle.
Agilent Technologies (NYSE:A) moved to significantly expand its clinical oncology presence on Monday, announcing an all-cash deal for Biocare Medical that adds a high-growth portfolio of cancer-staining antibodies and reagents.
Iran's Assembly of Experts has named Mojtaba Khamenei as the nation’s third Supreme Leader.
Adial Pharmaceuticals (NASDAQ:ADIL) reported a significant reduction in annual net losses for 2025, as the clinical-stage biotech firm secures FDA alignment and strategic partnerships to transition its lead alcohol-use disorder candidate into Phase 3 trials.
Global energy markets are reeling as oil tracks toward its most significant weekly gain in four years, fuelled by escalating conflict in the Middle East.
Diana Shipping escalated its pursuit of Genco Shipping & Trading on Friday, raising its all-cash offer to $23.50 per share in a sweetened bid backed by a $1.43 billion financing package and a strategic vessel-sale agreement with Star Bulk Carriers.
Imperial Petroleum reported a surge in fourth-quarter revenue and sustained annual profitability, as the Athens-based shipowner leverages a debt-free balance sheet to aggressively expand its presence in the tanker and drybulk markets.
Tsakos Energy Navigation (NYSE:TEN) posted a sharp rise in full-year profitability for 2025, as the Greek tanker major capitalized on high fleet utilization and a strategic push into the LNG and specialized vessel markets.
SunCar Technology Group (NASDAQ:SDA) issued a bullish outlook for the coming fiscal year, forecasting a 20% jump in revenue as the digital auto platform leverages artificial intelligence and deepening electric vehicle (EV) partnerships to drive profitability.
Halozyme Therapeutics (NASDAQ:HALO) shares were in focus Friday after partner Johnson & Johnson secured U.S. regulatory approval for a subcutaneous combination therapy that significantly reduces the risk of disease progression in patients with relapsed multiple myeloma.
Hurco Companies (NASDAQ:HURC) reported a reduced net loss for the first quarter of fiscal 2026, finding a silver lining in a double-digit surge in domestic orders despite a dip in global sales.
PMV Pharmaceuticals (NASDAQ:PMVP) reported significant clinical momentum for its lead candidate, rezatapopt, bolstered by a fresh FDA Orphan Drug Designation and clinical results showing high response rates in late-stage ovarian cancer patients.
Cohen & Company (NYSE:COHN) capped a transformative fiscal year with a massive top-line expansion, fueled by a 246% year-over-year revenue increase that prompted the board to reward shareholders with both a quarterly and a special dividend.
Mammoth Energy Services (NASDAQ:TUSK) capped off a year of aggressive restructuring, reporting full-year 2025 results that highlight a dramatic shift from traditional oilfield services toward a specialized aviation and rental platform.
The U.S. government has begun denying requests from companies seeking refunds for billions of dollars in illegal tariffs, despite a landmark Supreme Court ruling that struck down the levies last month.
Immuneering (NASDAQ:IMRX) has achieved a 64% overall survival rate at 12 months in an ongoing Phase 2a clinical trial for its lead drug candidate, atebimetinib, in combination with chemotherapy for patients with metastatic pancreatic cancer.
Jade Biosciences (NASDAQ:JBIO) reported fourth-quarter and full-year 2025 financial results on Friday, highlighting a robust cash position and a clear clinical roadmap for its portfolio of monoclonal antibodies.
AtaiBeckley (NASDAQ:ATAI) reported fourth-quarter and full-year 2025 results on Friday, marking its first annual report since the transformative merger of atai Life Sciences and Beckley Psytech.
Genesco (NYSE:GCO) reported fourth-quarter and full-year fiscal 2026 results on Friday that significantly outpaced the prior year, driven by a powerful holiday performance at its Journeys and Johnston & Murphy banners.
Embraer (NYSE:EMBJ) reported fourth-quarter and full-year 2025 results on Friday that significantly outpaced Wall Street projections, fueled by a year-end surge in aircraft deliveries and expanding margins.
Bluejay Diagnostics (NASDAQ:BJDX) issued a corporate update on Friday detailing its 2026 operational roadmap, focused on the regulatory path for its Symphony™ System and its flagship IL-6 clinical test.
Algonquin Power & Utilities (NYSE:AQN) reported a significant financial turnaround for fiscal 2025 on Friday, transitioning from a prior-year loss to a net profit of $208 million.
MarketWise (NASDAQ:MKTW) reported fourth-quarter and full-year 2025 results on Friday, highlighting a successful pivot toward higher-value products that drove billings and cash flow well above company guidance.
